Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced that data from its Phase 2 study APC-004 will be featured in an oral presentation at World Sleep 2022 in Rome, Italy on Monday, March 14.
March 9, 2022
· 4 min read